Literature DB >> 21094127

Adenosine and its receptors in the heart: regulation, retaliation and adaptation.

John P Headrick1, Jason N Peart, Melissa E Reichelt, Luke J Haseler.   

Abstract

The purine nucleoside adenosine is an important regulator within the cardiovascular system, and throughout the body. Released in response to perturbations in energy state, among other stimuli, local adenosine interacts with 4 adenosine receptor sub-types on constituent cardiac and vascular cells: A(1), A(2A), A(2B), and A(3)ARs. These G-protein coupled receptors mediate varied responses, from modulation of coronary flow, heart rate and contraction, to cardioprotection, inflammatory regulation, and control of cell growth and tissue remodeling. Research also unveils an increasingly complex interplay between members of the adenosine receptor family, and with other receptor groups. Given generally favorable effects of adenosine receptor activity (e.g. improving the balance between myocardial energy utilization and supply, limiting injury and adverse remodeling, suppressing inflammation), the adenosine receptor system is an attractive target for therapeutic manipulation. Cardiovascular adenosine receptor-based therapies are already in place, and trials of new treatments underway. Although the complex interplay between adenosine receptors and other receptors, and their wide distribution and functions, pose challenges to implementation of site/target specific cardiovascular therapy, the potential of adenosinergic pharmacotherapy can be more fully realized with greater understanding of the roles of adenosine receptors under physiological and pathological conditions. This review addresses some of the major known and proposed actions of adenosine and adenosine receptors in the heart and vessels, focusing on the ability of the adenosine receptor system to regulate cell function, retaliate against injurious stressors, and mediate longer-term adaptive responses.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21094127     DOI: 10.1016/j.bbamem.2010.11.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  46 in total

1.  Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury.

Authors:  Ming Cai; Zachary M Huttinger; Heng He; Weizhi Zhang; Feng Li; Lauren A Goodman; Debra G Wheeler; Lawrence J Druhan; Jay L Zweier; Karen M Dwyer; Guanglong He; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2011-09-12       Impact factor: 5.000

2.  Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.

Authors:  Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  Am J Pathol       Date:  2012-05-18       Impact factor: 4.307

Review 3.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

4.  Response by Li et al to Letter Regarding Article, "Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria Due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart".

Authors:  Ning Li; Brian J Hansen; Vadim V Fedorov
Journal:  Circulation       Date:  2016-12-06       Impact factor: 29.690

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Transcriptomic effects of adenosine 2A receptor deletion in healthy and endotoxemic murine myocardium.

Authors:  Kevin J Ashton; Melissa E Reichelt; S Jamal Mustafa; Bunyen Teng; Catherine Ledent; Lea M D Delbridge; Polly A Hofmann; R Ray Morrison; John P Headrick
Journal:  Purinergic Signal       Date:  2016-09-30       Impact factor: 3.765

7.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

8.  Enhanced A2A adenosine receptor-mediated increase in coronary flow in type I diabetic mice.

Authors:  Hicham Labazi; Bunyen Teng; Zhichao Zhou; S Jamal Mustafa
Journal:  J Mol Cell Cardiol       Date:  2015-12-02       Impact factor: 5.000

9.  Adenosine-Induced Atrial Fibrillation: Localized Reentrant Drivers in Lateral Right Atria due to Heterogeneous Expression of Adenosine A1 Receptors and GIRK4 Subunits in the Human Heart.

Authors:  Ning Li; Thomas A Csepe; Brian J Hansen; Lidiya V Sul; Anuradha Kalyanasundaram; Stanislav O Zakharkin; Jichao Zhao; Avirup Guha; David R Van Wagoner; Ahmet Kilic; Peter J Mohler; Paul M L Janssen; Brandon J Biesiadecki; John D Hummel; Raul Weiss; Vadim V Fedorov
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

Review 10.  Adenosine--a physiological or pathophysiological agent?

Authors:  Bertil B Fredholm
Journal:  J Mol Med (Berl)       Date:  2013-12-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.